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ACIP Smallpox Vaccination Recomendations: Summary
O cto b e r 17, 2002 
B a ckg ro un d
In June 2001, The Advisory Committee on Immunization Practices (ACIP) made recommendations fo r the use of 
sm allpox (vaccinia) vaccine to protect persons who work with orthopoxviruses, to prepare fo r a possible 
b ioterrorism  attack, and to respond to an attack involving sm allpox. This recommendation was followed in June 
2002 with draft supplem ental recommendations that extended the ACIP 's sm allpox vaccination recommendation 
to include people designated to respond or care fo r a suspected or confirmed case o f smallpox. Specifically, the 
ACIP recommended voluntary vaccination o f people serving on w hat subsequently have been designated as 1)
“ Sm allpox Public Health Team s” and 2) “ Sm allpox Health Care Team s” . The June 2002 draft supplemental 
sm allpox vaccine recommendations also clarified and expanded the primary strategy fo r control and containm ent 
o f sm allpox in the event o f an outbreak.
In September, the Centers fo r Disease Control and Prevention (CDC) asked the ACIP to provide additional 
guidance on eight sm allpox vaccination implementation issues, including the scope and composition o f the 
Sm allpox Health Care Teams. The eight issues were: 1) types o f healthcare workers that should included in 
Sm allpox Health Care Teams; 2) care o f the sm allpox vaccination site; 3) need fo r administrative leave for 
vaccinated healthcare workers; 4) screening fo r atopic dermatitis as a contraindication fo r vaccination; 5) 
screening fo r pregnancy as a contraindication fo r sm allpox vaccination; 6) screening fo r HIV infection as a 
contraindication fo r sm allpox vaccination; 7) simultaneous administration o f sm allpox vaccines with other 
vaccines; and 8) vaccination of sm allpox vaccinators.
The ACIP 's recomm endations reflect consultation with CDC's Hospital Infection Control Practices Advisory 
Committee (HICPAC) and DHHS's National Vaccine Advisory Committee (NVAC). The ACIP recommendations 
are being forwarded to HICPAC for the ir review and consideration on October 22 and 23, 2002. The Healthcare 
Infection Control Practices Advisory Committee provides advice and guidance to CDC and DHHS regarding 
infection control practices and strategies fo r surveillance, prevention, and control o f health care- associated 
infections (e.g., nosocomial infections), antim icrobial resistance and related events in settings where healthcare is 
provided (e.g., hospitals, long-term care facilities, and home health agencies).
In the coming weeks, the jo in t ACIP-HICPAC recommendations w ill be forwarded to CDC and DHHS fo r their 
review and consideration.
S m a llp o x  H ealth  Care Team s
The June 2002 draft supplemental recommendations recommended that states should designate initial sm allpox 
isolation care facilities (type C facilities) and these facilities, in turn, should pre-designate individuals who would 
care fo r sm allpox patients fo r vaccination. However, further discussions with state health officials and hospital 
adm inistrators identified problems with this approach. It was problematic to designate type C hospitals since 
suspected sm allpox patients are likely to present at the hospitals which are the ir usual source o f care, and not 
only at designated hospitals. Therefore, health and bio-terrorism  officials indicated it was preferable to offer all 
acute care hospitals the opportunity to establish Sm allpox Health Care Teams.
O ct. 17, 2002: AC IP R eco m m e nd a tio ns  R egard ing  th e  E ig h t Issues: A  B r ie f S um m ary
Sm allpox Health Care Teams
The ACIP recommends that in the first stages o f a pre-event sm allpox vaccination program, each acute care 
hospital that has functioning airborne infection isolation room(s) identify a group o f healthcare workers who would 
be vaccinated and trained to provide in-room medical care fo r the first few sm allpox patients requiring hospital 
admission and to evaluate and manage patients who present to the Emergency Department with suspected 
smallpox. For the first 7-10 days after patients with sm allpox have been identified, this team  would be hospital- 
based and provide care 24 hours a day, using 8-12 hour shifts. Non-essential workers would be restricted from 
entering into the rooms o f patients with smallpox.
The ACIP recommends that Sm allpox Health Care Teams include: 1) Em ergency Room Staff, including both 
physicians and nurses; 2) Intensive Care Unit staff, including physicians, nurses, and in hospitals that care for 
infants and children, this encompass pediatricians, pediatric intensivists, and pediatric emergency room 
physicians and nurses; 3) General Medical Unit staff, including physicians, internists, pediatricians, obstetricians, 
and fam ily physicians in institutions where these individuals are the essential providers o f primary medical care; 4) 
Medical house sta ff (i.e., selected medical, pediatric, obstetric, and fam ily physicians); 5) Medical subspecialists, 
including infectious disease specialists [this may also involve the creation o f Regional team s of subspecialists 
(e.g., local medical consultants with
sm allpox experience, dermatologists, ophthalmologists, pathologists, surgeons, anesthesiologists in facilities 
where intensivists are not trained in anesthesia) to deliver consultative services; 6) infection control professionals 
(ICPs); 7) respiratory therapists; 8) radiology technicians; 9) security personnel; and 10) housekeeping sta ff (e.g., 
those sta ff involved in maintaining the health care environment and decreasing the risk o f fomite transmission).
Overall, each Sm allpox Health Care Team m ight include about 15 emergency room doctors and nurses, 15 
intensive care unit doctors and nurses, and a total o f 10-15 personnel from the other areas. It is anticipated that 
the size and composition o f a sm allpox medical care team  will vary according to the individual institutions and 
the ir patient populations. It is also recognized that each hospital should consider having at least two Sm allpox 
Health Care Team s to ensure continuity o f care. Sm allpox vaccination would be voluntary.
Clinical laboratory workers are not included in the initial phase o f pre-event sm allpox vaccination because the 
quantity o f virus likely to be in clinical specimens o f blood and body fluids is low. Consistent adherence to 
standard precautions and ASM/CDC protocols w ill prevent exposure to virus in clinical specimens. Although it is 
not recommended that emergency medical technicians (EMTs), as a group, be vaccinated in this first phase,
individual hospitals may identify and include hospital-based EMTs (i.e., personnel who would be dispatched to 
transport patients with suspected smallpox) on the ir Sm allpox Health Care Teams.
Sm allpox Vaccination Site Care
Following sm allpox vaccination, the ACIP recommends that health-care workers involved in direct patient care 
should keep the ir vaccination sites covered with gauze or a s im ilar absorbent material in order to absorb exudates 
that would develop. This dressing should, in turn, be covered with a sem i-perm eable dressing to provide a barrier 
to vaccinia virus. Use o f a sem i-perm eable dressing alone could cause 1) maceration o f the vaccination site and 
2) increased prolonged irritation and itching at the site, thereby increasing touching, scratching and contamination 
o f the hands. Products combining an absorbent base with an overlying sem i-perm eable layer can be used to 
cover the vaccination site. The vaccination site should be covered during direct patient care until the scab 
separates.
Vaccinia is generally transm itted by direct person-to-person and close contact (within 6 feet), and infection control 
precautions should be taken to reduce this likelihood. The most critical measure in preventing inadvertent 
implantation and contact transm ission from the vaccinia vaccination site is thorough hand-hygiene after changing 
the bandage or after any other contact with the vaccination site. Hospitals should include a site-care component 
to the ir sm allpox vaccination programs in which designated, vaccinated sta ff would assess dressings fo r all 
vaccinated health-care workers daily (whether involved in direct patient care or in other duties), determ ine if 
dressings needed changing, and then change the dressing if indicated. This designated sta ff would assess the 
vaccination site fo r local reactions and fo r vaccine take. They should also use the opportunity to reinforce 
messages to vaccinees about the need fo r meticulous hand-hygiene.
T ransmission o f vaccinia is also a concern in other settings when close personal contact with children or other 
persons is likely—for example, parenting o f infants and young children. In these situations, the vaccination site 
should be covered with gauze or a sim ilar absorbent material, and a shirt or other clothing should be worn, and 
careful attention to hand hygiene (hand washing) practiced.
Adm inistrative Leave fo r Vaccinated Health Care W orkers
Adm inistrative leave is not required routinely fo r newly vaccinated healthcare workers unless they are physically 
unable to w ork due to system ic signs and symptoms o f illness, extensive skin lesions which cannot be adequately 
covered, or if they do not adhere to the recommended infection control precautions. It is important to realize that 
the very close contact required fo r transm ission o f vaccinia to household contacts is unlikely to occur in the 
healthcare setting.
However, it is also recommended that vaccination o f Sm allpox Health Care Team members be phased in, starting 
with a small number o f hospitals. Within a single institution, it would be prudent to designate a small proportion, 
e.g. 20-30% o f the candidate healthcare workers, fo r the first phase o f vaccinations to allow institutions to gain 
experience in post-vaccination management. The ACIP recognizes that the incidence o f adverse events following 
vaccination o f previously vaccinated persons is substantially less than in primary vaccinees, and therefore 
recommends that when feasible, previously vaccinated health care workers be included in th is stage 1 vaccination 
program. It is also advisable to stagger vaccination o f healthcare workers within an individual patient care unit by
three weeks in order to m inimize the number o f vaccinated individuals who would be on sick leave concurrently in 
association with system ic effects o f the vaccine, which usually occur at days 8-10 after inoculation.
Screening fo r A topic Dermatitis as a Contraindication fo r Vaccination
Atopic dermatitis, irrespective o f disease severity or activity, is a risk factor fo r developing eczema vaccinatum 
following sm allpox vaccination in e ither vaccinees or in the ir close contacts. Due to the increased risk fo r eczema 
vaccinatum, sm allpox (vaccinia) vaccine should not be administered to persons with a history o f eczema or atopic 
dermatitis, irrespective o f disease severity or activity. Additionally, persons with household contacts that have a 
history o f eczema or atopic dermatitis, irrespective o f disease severity or activity, are not eligible fo r sm allpox 
(vaccinia) vaccination because o f the increased risk that the ir household contacts may develop eczema 
vaccinatum. The literature also reports that persons with Darier's disease can develop eczema vaccinatum and 
therefore should not be vaccinated.
Persons with other acute, chronic, or exfoliative conditions (e.g., burns, impetigo, varicella zoster, herpes, severe 
acne, or psoriasis) are at higher risk fo r inadvertent inoculation and should not be vaccinated until the condition 
resolves.
Screening fo r Pregnancy as a Contraindication fo r Vaccination
Fetal vaccinia is a very rare, but serious, complication o f sm allpox vaccination during pregnancy or shortly before 
conception. Therefore, vaccinia vaccine should not be administered in a pre-event setting to pregnant women or 
to women who are trying to become pregnant. Before vaccination, women o f child-bearing age should be asked if 
they are pregnant or intend to become pregnant in the next 4 weeks; women who respond positively should not 
be vaccinated. In addition, the potential risk to the fetus should be explained and women who are vaccinated 
counseled not to become pregnant during the 4 weeks after vaccination. Routine pregnancy testing o f women of 
child-bearing age is not recommended.
To further reduce the risk o f inadvertently vaccinating a woman who is pregnant, at the time o f pre-screening, 
women o f child-bearing age should be educated about fetal vaccinia, and abstinence or contraception to reduce 
the risk o f pregnancy before or within four weeks after vaccination. Any woman who thinks she could be pregnant 
or who wants additional assurance that she is not pregnant should perform a urine pregnancy test with a “ first 
m orning” void urine on the day scheduled for vaccination. Such tests could be made available at the pre­
screening and vaccination sites to avoid cost or access barriers to testing.
If a pregnant woman is inadvertently vaccinated or if she becomes pregnant within 4 weeks after vaccinia 
vaccination, she should be counseled regarding the basis o f concern fo r the fetus. However, vaccination during 
pregnancy should not ordinarily be a reason to term inate pregnancy. To expand understanding o f the risk o f fetal 
vaccinia and to docum ent whether adverse pregnancy outcome may be associated with vaccination, a pregnancy 
registry should be maintained and any adverse outcomes carefully investigated.
Screening fo r HIV Infection as a Contraindication fo r Vaccination
Persons with HIV infection or AIDS are at increased risk o f progressive vaccinia (vaccinia necrosum) following 
vaccinia vaccination. Therefore, vaccinia vaccine should not be administered to persons with HIV infection or
AIDS. Before vaccination, potential vaccinees should be educated about the risk of severe vaccinial complications 
among persons with HIV infection or other immunosuppressive conditions; persons who th ink they may have one 
o f these conditions should not be vaccinated.
The ACIP does not recommend mandatory HIV testing prior to sm allpox vaccination, but recommends that HIV 
testing should be readily available to all persons considering sm allpox vaccination. HIV testing is recommended 
fo r persons who have any history o f a risk factor fo r HIV infection and who are not sure o f their HIV infection 
status. Because known risk factors cannot be identified fo r some persons with HIV infection, anyone who is 
concerned that they could have HIV infection also should be tested. HIV testing should be available in a 
confidential or, where permitted by law, anonymous setting with results communicated to the potential vaccinee 
before the planned date o f vaccination. Persons with a positive test result should be told not to present to the 
vaccination site fo r immunization. Information about local testing options should be provided to all potential 
vaccinees, including sites where testing is performed at no cost.
Simultaneous Adm inistration o f Sm allpox Vaccine with other Vaccines
Vaccinia vaccine may be administered sim ultaneously with any inactivated vaccine, such as influenza vaccine, to 
encourage appropriate receipt o f all indicated vaccines, e.g., in populations such as health care workers. W ith the 
exception o f varicella vaccine, vaccinia vaccine may be administered sim ultaneously with other live virus 
vaccines. To avoid confusion in ascertaining which vaccine may have caused post-vaccination skin lesions or 
other adverse events, and facilitate managing such events, varicella vaccine and vaccinia vaccine should only be 
administered >4 weeks apart.
Vaccination o f Sm allpox Vaccinators
In order to m inimize the clinical impact o f inadvertent inoculation, should it occur, ACIP recommends that persons 
handling and administering sm allpox vaccine in the proposed pre-event sm allpox vaccination program be 
vaccinated. Vaccination o f th is group w ill also contribute to preparedness fo r sm allpox response, should a 
sm allpox release occur, with developm ent o f a cadre o f vaccinated, experienced vaccinators who could 
immediately be deployed fo r outbreak response
The Centers fo r  Disease C ontro l and Prevention (CDC) p ro tec ts  people's hea lth  and  sa fe ty  b y  p reven ting  and  
contro lling  diseases and  in ju rie s ; enhances hea lth  decisions by p rov id ing  credib le in fo rm a tion  on c ritica l health  
issues; and  prom otes hea lthy liv in g  through s trong  partne rsh ips w ith  loca l, na tiona l and  in te rna tiona l
organizations.
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